{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-025476","form_type":"8-K","ticker":"IRD","cik":"0001228627","company_name":"Opus Genetics, Inc.","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.612077+00:00","generated_at":"2026-06-02T03:23:46.402080+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ocuphire Pharma presents NPDR subset analysis from ZETA-1 Phase 2 trial for APX3330","bullets":["Subset analysis: 3% of APX3330 vs 20% of placebo had ≥3-step worsening on binocular DRSS at Week 24.","7% of APX3330 vs 27% of placebo developed PDR (DRSS ≥61) in either eye at Week 24.","APX3330 was well-tolerated; ocular AEs similar between groups, pruritus mild/self-limited.","NPDR subset includes moderate-to-severe NPDR patients without CI-DME at baseline.","Results inform planned trial of APX3330 to slow PDR conversion in high-risk NPDR."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-025476","json":"https://secwatch.observer/filing/0001140361-24-025476.json","markdown":"https://secwatch.observer/filing/0001140361-24-025476.md","text":"https://secwatch.observer/filing/0001140361-24-025476.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1228627/000114036124025476/0001140361-24-025476-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1228627/000114036124025476/ef20028889_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T03:23:46.402080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}